Nurix Therapeutics, Inc. (NRIX) vs Pharvaris N.V. (PHVS)

Nurix Therapeutics, Inc. and Pharvaris N.V. are both Biotechnology companies. Nurix Therapeutics, Inc. and Pharvaris N.V. are of similar size ($2.5B and $2.3B). Pharvaris N.V. has the higher net margin (0.00% vs −928.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Pharvaris N.V. leads on 9 and Nurix Therapeutics, Inc. on 4.

Valuation

Metric NRIX PHVS Biotechnology median
P/E n/m n/m 7.88
P/S 69.73 n/m 11.47
P/B 6.37 6.23 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 57.67 n/m 10.73
Earnings yield (14.95%) (9.53%) (28.84%)
Free cash flow yield (11.88%) (8.17%) (23.03%)

Profitability

Metric NRIX PHVS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (982.37%) 0.00% 0.00%
Net margin (928.44%) 0.00% 0.00%
Free cash flow margin (828.28%) 0.00% 0.00%
Return on equity (80.30%) (71.50%) (57.72%)
Return on assets (60.57%) (64.43%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NRIX PHVS Biotechnology median
Revenue growth (TTM) (58.40%) — 5.64%
EPS growth (last fiscal year) (5.90%) (25.37%) —
Revenue growth, 5-year CAGR 36.35% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NRIX PHVS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.34 11.94 4.73
Net debt to EBITDA 2.14 1.72 0.96

Dividend

Metric NRIX PHVS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric NRIX PHVS Biotechnology median
Market cap 2.45b 2.30b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack